Daiwa Securities Group
IBRX icon

Daiwa Securities Group’s ImmunityBio IBRX Stock Holding History

Daiwa Securities Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757K Sell
86,500
-112,700
-57% -$853K ﹤0.01% 889
2026
Q1 		$464K Buy
+199,200
New +$1.36M ﹤0.01% 928

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Daiwa Securities Group's IBRX Position: Q2 2026 in Review

Daiwa Securities Group reduced its ImmunityBio (IBRX) stake by 57% in Q2 2026, selling an estimated $853K and leaving 86,500 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #888.

Daiwa Securities Group first reported a position in IBRX in Q1 2018 and has held it in 26 quarters since. The position peaked at $1.53M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Daiwa Securities Group held 86,500 shares of ImmunityBio worth $757K as of Q2 2026.
  • Daiwa Securities Group sold 112,700 ImmunityBio shares in Q2 2026, an estimated $853K.
  • ImmunityBio made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #888 holding.
  • Daiwa Securities Group first reported a position in ImmunityBio in Q1 2018 and has held it in 26 quarters since.
  • Daiwa Securities Group's ImmunityBio position peaked at $1.53M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.